European Heart Journal

Papers
(The H4-Index of European Heart Journal is 92. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)
ArticleCitations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure6739
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice3119
2021 ESC/EACTS Guidelines for the management of valvular heart disease2660
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension1510
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death1113
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio1046
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy1024
2023 ESC Guidelines for the management of acute coronary syndromes933
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe626
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases582
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure546
2023 ESC Guidelines for the management of cardiomyopathies512
European Society of Cardiology: cardiovascular disease statistics 2021496
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis463
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement452
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery437
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research425
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather396
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus376
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes346
2023 ESC Guidelines for the management of endocarditis345
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force318
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance288
C-reactive protein and clinical outcomes in patients with COVID-19277
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement268
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions268
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study221
Left bundle branch area pacing outcomes: the multicentre European MELOS study220
Prevalence of statin intolerance: a meta-analysis216
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o213
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies199
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study197
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement189
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials186
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)185
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy176
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists172
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis166
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction166
Heart failure drug treatment: the fantastic four157
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study156
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies151
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism151
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction151
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults149
Empagliflozin in acute myocardial infarction: the EMMY trial148
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial147
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank147
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery147
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials144
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank143
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial139
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial136
Application of artificial intelligence to the electrocardiogram135
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF135
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)134
Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes131
Mendelian randomization for cardiovascular diseases: principles and applications129
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis127
Electrocardiogram screening for aortic valve stenosis using artificial intelligence124
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme123
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial123
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk122
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study118
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial115
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis114
Colchicine and the heart112
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality107
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials105
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s105
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk104
Combination lipid-lowering therapy as first-line strategy in very high-risk patients104
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study104
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials103
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial102
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial101
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease101
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study100
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study100
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial99
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)98
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial98
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group97
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry96
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations95
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial95
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th95
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial94
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction94
Sex differences in arterial hypertension93
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy92
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction92
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up92
High-density lipoprotein revisited: biological functions and clinical relevance92
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome92
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study92
0.22932600975037